Key Insights

Highlights

Treatment Research

1 treatments under study, led by Catch T Cells

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05103631Phase 1Active Not Recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Catch T Cells1

Active Sponsors

  • Center for Cell and Gene Therapy, Baylor College of Medicine1
  • The Methodist Hospital Research Institute1
  • Baylor College of Medicine1

Top Investigators

Related Conditions

  • Liver Cell Carcinoma1
  • Solid Tumor1
  • Wilms Tumor1
  • Liposarcoma1
  • Yolk Sac Tumor1

Activity Timeline